Research: Tumor-immune regulation by Dishevelled (DVL) proteins in triple-negative breast cancer (TNBC) Area of Focus : Tumor immunology and Wnt signaling
Figure 1: Schematic representation of the proposed role of DVL2 in regulating the tumor immune microenvironment. Loss of DVL2 is proposed to enhance tumor immunogenicity through increased MHC-I antigen presentation and the induction of pro-inflammatory signals. Figure 2: Experimental workflow for in vivo tumor studies. Control and DVL- deficient tumor cells were orthotopically injected into mice and tumor growth was monitored over time. At endpoints, tumors and relevant tissues were harvested for downstream analyses, to evaluate the tumor immune microenvironment. Figure 3: Functional model of DVL2 knockout tumors. Loss of DVL2 promotes CD8⁺ T- cell infiltration and activation resulting in cytotoxic T cell mediated tumor cell apoptosis.
Open Questions
Does DVL2 suppress tumor immunogenicity via MHC-I regulation?
What signaling pathways drive immune cell recruitment upon DVL2 loss?
Is the anti-tumor effect of DVL2 loss CD8⁺ T-cell dependent?
How does DVL2 loss reprogram the tumor immune microenvironment?
